Coherus Oncology Files 8-K with Financial Data

TL;DR

Coherus Oncology filed an 8-K detailing past capital raises and research spending.

AI Summary

On November 13, 2025, Coherus Oncology, Inc. filed an 8-K report. The filing indicates historical financial data, including details on additional paid-in capital from various offerings and stock purchase agreements between 2022 and 2024. It also mentions research activities and domestic country operations.

Why It Matters

This filing provides a historical snapshot of Coherus Oncology's financial activities, including capital raises and research investments, which can inform investors about the company's financial health and strategic focus.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting historical financial data and does not announce new material events or significant changes.

Key Numbers

• 2022-2024 — Reporting Period for Financial Data (Covers historical data on additional paid-in capital and research activities.)
• 20251113 — Filing Date (Date the 8-K was submitted to the SEC.)

Key Players & Entities

• Coherus Oncology, Inc. (company) — Filer
• Dennis M. Lanfear (person) — Contact Person
• 0001104659-25-111484 (filing_id) — Accession Number
• 20251113 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
• $483.4 m — for upfront, all-cash consideration of $483.4 million, inclusive of $118.4 million for
• $118.4 million — eration of $483.4 million, inclusive of $118.4 million for UDENYCA product inventory. In addit
• $37.5 million — ive two additional earn-out payments of $37.5 million each. The UDENYCA Sale represented th

Filing Documents

• chrs-20251113x8k.htm (8-K) — 259KB
• chrs-20251113xex23d1.htm (EX-23.1) — 9KB
• chrs-20251113xex99d1.htm (EX-99.1) — 2367KB
• 0001104659-25-111484.txt ( ) — 16069KB
• chrs-20251113.xsd (EX-101.SCH) — 133KB
• chrs-20251113_cal.xml (EX-101.CAL) — 145KB
• chrs-20251113_def.xml (EX-101.DEF) — 606KB
• chrs-20251113_lab.xml (EX-101.LAB) — 1040KB
• chrs-20251113_pre.xml (EX-101.PRE) — 940KB
• chrs-20251113x8k_htm.xml (XML) — 3163KB

01 Other Events

Item 8.01 Other Events. Coherus Oncology, Inc. (the "Company") is filing this Current Report on Form 8-K (this "Form 8-K"), including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the "SEC") on March 17, 2025 (the "2024 Form 10-K") to provide retrospective discontinued operations presentation for the years ended December 31, 2024 and 2023 reflected in the 2024 Form 10-K. The recast financial information is attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to incorporate by reference into a registration statement on Form S-3 expected to be filed by the Company on November 13, 2025. On December 2, 2024, the Company and Intas Pharmaceuticals Ltd. ("Intas") entered into an asset purchase agreement (the "UDENYCA Purchase Agreement"), pursuant to which, and upon the terms and subject to the conditions thereof, the Company agreed to divest the UDENYCA franchise (the "UDENYCA Business") to Intas (the "UDENYCA Sale"). On April 11, 2025, the Company completed the divestiture of the UDENYCA Business to Intas for upfront, all-cash consideration of $483.4 million, inclusive of $118.4 million for UDENYCA product inventory. In addition, the Company is also eligible to receive two additional earn-out payments of $37.5 million each. The UDENYCA Sale represented the last and most significant divestiture of the Company's biosimilar businesses, which comprised the UDENYCA, YUSIMRY and CIMERLI franchises; representing a strategic shift resulting in a major effect on the Company's business and therefore met the criteria for classification as discontinued operations. Accordingly, starting with the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, the Company began to classify its condensed consolidated financial statem

, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations"

Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations"

, Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" and

Part II, Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" and

, Item 8. "Financial Statements and Supplementary Data"

Part II, Item 8. "Financial Statements and Supplementary Data"

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 23.1 Consent of Independent Registered Public Accounting Firm 99.1 Updated Part II, Items 7. and 7A. "Management's Discussion and Analysis of Financial Condition and Results of Operations and Quantitative and Qualitative Disclosures About Market Risk," and Part II, Item 8. "Financial Statements and Supplementary Data" of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 101.INS 101.SCH 101.CAL 101.DEF 101.LAB 101.PRE Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document Inline XBRL Taxonomy Extension Schema Document Inline XBRL Taxonomy Extension Calculation Linkbase Document Inline XBRL Taxonomy Extension Definition Linkbase Document Inline XBRL Taxonomy Extension Label Linkbase Document Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 13, 2025 COHERUS ONCOLOGY, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR